Topic: Asia Pacific’s Fast-Changing Life Sciences Business Landscape: The 5 Most Vexing Questions and Practical Tips for Navigating Grey Areas
The life sciences market in China remains strategically important with its predicted growth and market size. However, the business environment within China will likely continue to change and shift due to geopolitical tensions, macroeconomic and policy changes. To help build or maintain a successful life sciences business in China, what compliance questions should multinationals be addressing about the realities of operating in China, and navigating known and unknown risk factors?
- China’s structural transformation of its healthcare system and critical compliance implications for life science companies
- Navigating potential fraudulent expenses: Fapaio fraud and various schemes for misusing them
- Navigating WeChat communication landmines: Document sharing, data retention
- Data protection and privacy laws in China: Balancing global data privacy laws with DOJ and SEC expectations for FCPA compliance
- Mitigating new compliance risks posed by China’s new social credit system
- What go-to-market considerations are most important to craft a winning strategy in response to China’s health reforms?
- How multinationals are evolving their programs in response to global trade tensions relating to China
- Ashley Watson, Johnson & Johnson
- David Ralston, Taysha Gene Therapies
- Yuet Ming Tham, Sidley